Compare Gilead Sciences, Inc. (GILD) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Synopsys, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.69 (market cap $163.51B), while Synopsys, Inc. trades at $417.8 (market cap $81.43B). The key difference: Gilead Sciences, Inc. is far larger — about 2× Synopsys, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| GILD | SNPS | |
|---|---|---|
Market Cap | $163.51B | $81.43B |
Sector | Health | Technology |
52-Week High | $155.80 | $645.59 |
52-Week Low | $108.22 | $380.47 |
Enterprise Value | $178.05B | $89.79B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Synopsys (SNPS) trades at $423.37, down 0.57% on the day, with a bearish technical signal driven by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $3.68. Recent news highlights the company's strategic pivot toward AI-driven design tools and its role in the semiconductor ecosystem. Valuation ratios remain elevated, with a P/E of 97.32 and P/S of 8.98, reflecting high growth expectations.
The outlook for SNPS is supported by strong analyst sentiment, with 82.76% buy ratings and a consensus price target of $559.50, implying significant upside. However, risks include competitive pressures, execution challenges in integrating Ansys, and macroeconomic volatility affecting semiconductor demand. The stock's high valuation requires sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
